Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Goethe University of Frankfurt/Main, Hanau, Germany.
Br J Clin Pharmacol. 2012 Feb;73(2):170-4. doi: 10.1111/j.1365-2125.2011.04070.x.
Kava, a Pacific herb consumed worldwide for medicinal, recreational and cultural purposes, has been associated with rare hepatotoxicity, and there is currently a critical need to determine this causation. The previously proposed Pacific kava paradox was based on the theory that kava hepatotoxicity was not observed following use of traditional aqueous extracts in the Pacific region, but was restricted to use of Western acetonic and ethanolic extracts. Subsequent cases analyzed by the World Health Organization and published case reports revealed that traditional aqueous extracts used in New Caledonia, Australia, the USA and Germany may also be hepatotoxic; thus, there is no longer a basis to sustain the previously proposed Pacific kava paradox. It appears that the primary cause of toxicity may reside in the time before the preparation of the various kava extracts, possibly attributed to poor quality of the raw material caused by mould hepatotoxins. Rigorous testing of kava raw material is urgently advised, in addition to Pan-Pacific kava manufacturing quality standards.
卡瓦,一种在全球范围内被用于药用、娱乐和文化目的的太平洋草药,已被证实具有罕见的肝毒性,目前迫切需要确定其因果关系。先前提出的太平洋卡瓦悖论是基于这样一种理论,即在太平洋地区使用传统的水提物时没有观察到卡瓦肝毒性,但仅限于使用西方的丙酮和乙醇提取物。世界卫生组织随后分析并公布的病例报告显示,在新喀里多尼亚、澳大利亚、美国和德国使用的传统水提物也可能具有肝毒性;因此,先前提出的太平洋卡瓦悖论已不再有依据。似乎毒性的主要原因可能存在于制备各种卡瓦提取物之前的时间,可能归因于原材料质量差,由霉菌肝毒素引起。除了泛太平洋卡瓦制造质量标准外,还迫切建议对卡瓦原料进行严格测试。